Chronic inflammation linked to less likelihood of healthy aging

Chronic exposure to high levels of interleukin-6 was associated with a significantly lower likelihood of healthy aging, according to a study in CMAJ (Canadian Medical Association Journal).

Interleukin-6 is marker of inflammation, and has been linked to a variety of age-related diseases, such as diabetes, heart disease and cognitive decline. Diet, chronic disease, smoking and other factors can cause inflammation. However, studies on chronic inflammation have generally looked at inflammation at only one point in time.

Researchers analyzed data on 3044 civil servants aged 35

More information: www.cmaj.ca/lookup/doi/10.1503/cmaj.122072

add to favorites email to friend print save as pdf

Related Stories

Researchers discover new way to block inflammation

Jul 01, 2013

Researchers at NYU Langone Medical Center have discovered a mechanism that triggers chronic inflammation in Alzheimer's, atherosclerosis and type-2 diabetes. The results, published today in Nature Immunology, suggest a comm ...

Inflammation links social adversity and diabetes

Jul 02, 2013

Diabetes is strongly associated with socioeconomic status (SES): low income, low education, and low occupational status are all linked to a higher risk for diabetes. Trying to understand the mechanisms underlying the association, ...

Obesity and asthma: Study finds a link in the genes

Jul 18, 2013

(Medical Xpress)—Genes linked to chronic inflammation in asthma may be more active in people who are obese, according to new research that uncovers several biological ties between obesity and asthma.

Recommended for you

Phthalates heighten risk for childhood asthma

Sep 17, 2014

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to demonstrate an association between childhood asthma and prenatal exposure to two phthalates used ...

ERS: Mepolizumab is glucocorticoid-sparing in asthma

Sep 09, 2014

(HealthDay)—For patients with eosinophilic asthma, mepolizumab has a glucocorticoid-sparing effect and reduces exacerbations when administered intravenously or subcutaneously, according to two studies published ...

User comments